| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8139 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2013-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b05bb91446a553f474a18951bd2500be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f730c0b1dc94915da692787c83c3ba56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35d5358bdeee718ddb1d10ca84a245be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4d1fc633a3e088925f0c34d65ea95f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd30ded18d8a71bdd9d05c63304f6b02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aed68a4a04f62d220352d923ca013c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_255a6b6b18d3e16d28e34d9d522fc07c |
| publicationDate |
2018-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2672255-T3 |
| titleOfInvention |
Biomarkers in the selection of treatment for heart failure |
| abstract |
A method for identifying a subject that is eligible for administration of a medicament, said medicament being an aldosterone antagonist, comprising a) determining the amount of the PlGF and sFlt-1 biomarkers in a blood, serum or plasma sample of a subject suffering from heart failure and b1) calculate a relationship between the amount of PlGF and the amount of sFlt-1 (or vice versa) and compare the calculated relationship with a reference relationship, thereby identifying a subject that is eligible for the administration of said aldosterone antagonist, or b2) compare the amounts determined in step a) with reference amounts, thereby identifying a subject that is eligible for the administration of said aldosterone antagonist. |
| priorityDate |
2012-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |